Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology)

Simple item page
dc.contributor.authorSüner A.
dc.contributor.authorAydin D.
dc.contributor.authorHacioǧlu M.B.
dc.contributor.authorDoǧu G.G.
dc.contributor.authorImamoǧlu G.I.
dc.contributor.authorMenekşe S.
dc.contributor.authorPilanci K.N.
dc.contributor.authorYazici Ö.K.
dc.contributor.authorKoca D.
dc.contributor.authorKaraaǧaç M.
dc.contributor.authorAkyol M.
dc.contributor.authorAkman T.
dc.contributor.authorErgen S.
dc.contributor.authorAvci N.
dc.contributor.authorKaçan T.
dc.contributor.authorBozkurt O.
dc.contributor.authorKefeli U.
dc.contributor.authorUrakçi Z.
dc.contributor.authorAraz M.
dc.contributor.authorArpaci E.
dc.contributor.authorHarputlu H.
dc.contributor.authorSevinç A.
dc.date.accessioned2024-07-22T08:12:05Z
dc.date.available2024-07-22T08:12:05Z
dc.date.issued2016
dc.description.abstractOBJECTIVE: Prostate cancer is among the most common cancers in males. Prostate cancer is androgen dependent in the beginning, but as time progresses, it becomes refractory to androgen deprivation treatment. At this stage, docetaxel has been used as standard treatment for years. Cabazitaxel has become the first chemotherapeutic agent which has been shown to increase survival for patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) that progresses after docetaxel. Phase 3 TROPIC study demonstrated that cabazitaxel prolongs survival. PATIENTS AND METHODS: In this study, we evaluated a total of 103 patients who took cabaz-itaxel chemotherapy for mCRPC diagnosis in 21 centers of Turkey, retrospectively. This study included patients who progressed despite doc-etaxel treatments, had ECOG performance score between 0-2, and used cabazitaxel treatment. Patients received cabazitaxel 25 mg/m2 at every 3 weeks, and prednisolone 5 mg twice a day. RESULTS: Median number of cabazitaxel cures was 5.03 (range: 1-17). Cabazitaxel response evaluation detected that 34% of the patients had a partial response, 22.3% had stable disease and 32% had a progressive disease. Grade 3-4 hema-tological toxicities were neutropenia (28.2%), neutropenic fever (14.5%), anemia (6.7%), and thrombocytopenia (3.8%). In our study, median progression-free survival (PFS) was 7.7 months and overall survival (OS) was 10.6 months. CONCLUSIONS: This study reflects toxicity profile of Turkish patients as a Caucasian race. We suggest that cabazitaxel is a safe and effective treatment option for mCRPC patients who progress after docetaxel. Moreover, ethnicity may play important roles both in treatment response and in toxicity profile.
dc.identifier.issn11283602
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15907
dc.language.isoEnglish
dc.publisherVerduci Editore
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntineoplastic Agents
dc.subjectDisease-Free Survival
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNeoplasm Metastasis
dc.subjectProstatic Neoplasms, Castration-Resistant
dc.subjectRetrospective Studies
dc.subjectTaxoids
dc.subjectTreatment Outcome
dc.subjectTurkey
dc.subjectantiandrogen
dc.subjectcabazitaxel
dc.subjectdocetaxel
dc.subjectgranulocyte colony stimulating factor
dc.subjectprednisolone
dc.subjectantineoplastic agent
dc.subjectcabazitaxel
dc.subjecttaxoid
dc.subjectadult
dc.subjectaged
dc.subjectanemia
dc.subjectanorexia
dc.subjectArticle
dc.subjectcancer center
dc.subjectcancer chemotherapy
dc.subjectcancer control
dc.subjectcancer diagnosis
dc.subjectcancer growth
dc.subjectcancer patient
dc.subjectcancer survival
dc.subjectcastration resistant prostate cancer
dc.subjectcontrolled study
dc.subjectdiarrhea
dc.subjectdisease severity
dc.subjectdrug dose reduction
dc.subjectdrug efficacy
dc.subjectdrug fatality
dc.subjectdrug safety
dc.subjectfatigue
dc.subjectfebrile neutropenia
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmedical society
dc.subjectmetastasis potential
dc.subjectnausea
dc.subjectneutropenia
dc.subjectorchiectomy
dc.subjectoverall survival
dc.subjectperipheral neuropathy
dc.subjectprogression free survival
dc.subjectprostate adenocarcinoma
dc.subjectretrospective study
dc.subjectsurvival time
dc.subjectthrombocytopenia
dc.subjecttreatment response
dc.subjectTurk (people)
dc.subjectvomiting
dc.subjectclinical trial
dc.subjectdisease free survival
dc.subjectepidemiology
dc.subjectmetastasis
dc.subjectmiddle aged
dc.subjectmortality
dc.subjectmulticenter study
dc.subjectpathology
dc.subjectProstatic Neoplasms, Castration-Resistant
dc.subjecttreatment outcome
dc.subjectTurkey
dc.subjectvery elderly
dc.titleEffectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology)
dc.typeArticle

Files

Collections

Scopus Koleksiyonu